×

Biotech and Pharmaceuticals Life Sciences

  • MORRIS PLAINS, N.J. _ Immunomedics Inc. on Thursday reported a loss of $118.7 million in its fiscal first quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 10 cents per share. Immunomedics shares have nearly tripled since the beginning of the year.

  • NEW YORK _ Stemline Therapeutics Inc. on Thursday reported a loss of $16.1 million in its third quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 57 cents per share. Stemline Therapeutics shares have risen 24 percent since the beginning of the year.

  • Nov 9- Dynavax Technologies Corp's twice-rejected hepatitis B vaccine was approved by the U.S. Food and Drug Administration on Thursday, marking the drug developer's first regulatory approval. The two-dose vaccine, Heplisav-B, is designed to enhance the body's immune response to the hepatitis B virus in adults aged 18 years and older. A panel of independent...

  • CAMBRIDGE, Mass. _ Catabasis Pharmaceuticls Inc. on Thursday reported a loss of $7 million in its third quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • LEXINGTON, Mass. _ Concert Pharmaceuticals Inc. on Thursday reported third-quarter net income of $128.1 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Lexington, Massachusetts- based company said it had net income of $5.44. This story was generated by Automated Insights using data from Zacks Investment Research.

  • BUFFALO, N.Y. _ Athenex Inc. on Thursday reported a loss of $23.3 million in its third quarter. The Buffalo, New York- based company said it had a loss of 41 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • PALO ALTO, Calif. _ Eiger BioPharmaceuticals Inc. on Thursday reported a loss of $9.2 million in its third quarter. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.27 per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • SINGAPORE _ Wave Life Sciences Pte. Ltd. on Thursday reported a loss of $26.1 million in its third quarter. The average estimate of three analysts surveyed by Zacks Investment Research was also for a loss of 94 cents per share. Four analysts surveyed by Zacks expected $765,000.

  • TEL AVIV, Israel _ Galmed Pharmaceuticals Ltd. on Thursday reported a loss of $2.8 million in its third quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share. Galmed Pharmaceuticals shares have increased 95 percent since the beginning of the year.

  • PARIS, Nov 9- Sanofi will develop and sell an oral treatment candidate for multiple sclerosis owned by U.S firm Principia Biopharma in a licensing agreement that could total $765 million, the French drugmaker said on Thursday. Under the terms of the deal, Principia will grant Sanofi an exclusive, worldwide license to develop and commercialise PRN2246, a drug...

  • PARIS, Nov 9- Sanofi will develop and sell an oral treatment candidate for multiple sclerosis owned by U.S firm Principia Biopharma in a licensing agreement that could total $765 million, the French drugmaker said on Thursday. Under the terms of the deal, Principia will grant Sanofi an exclusive, worldwide license to develop and commercialize PRN2246, a drug...

  • *Core third-quarter EPS $1.12 vs consensus $1.04. LONDON, Nov 9- AstraZeneca's drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes. Total revenue rose 9 percent to $6.23 billion in the quarter,...

  • Japan's top drugmaker has become more international under its French CEO Christophe Weber, who took over in 2015. Symptomatic dengue was recorded in 21, or 1.3 percent, of 1,596 Asian and Latin America children and adolescents vaccinated with TAK-003 compared with nine, or 4.5 percent, of 198 placebo recipients. In April this year, Takeda completed enrolment...

  • BOSTON, Nov 2- A former Puma Biotechnology Inc executive pleaded guilty on Thursday to U.S. charges that he traded on inside information ahead of announcements by the biopharmaceutical company about a drug it was developing to treat breast cancer. Robert Gadimian, the Los Angeles- based company's former senior director of regulatory affairs, pleaded guilty in...

  • Nov 2- More than half of patients with a rare, rapidly progressing often fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology, according to results of a late stage study presented on Thursday. Alnylam shares rose more than 17 percent, to $142.16.

  • Nov 2- More than half of patients with a rare, rapidly progressing often fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology, according to results of a late stage study presented on Thursday. Alnylam shares rose more than 17 percent, to $142.16.

  • Nov 2- More than half of patients with a rare, rapidly progressing often fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology, according to results of a late stage study released on Thursday. Alnylam shares rose more than 17 percent, to $142.16.

  • Nov 2- More than half of patients with a rare, rapidly progressing fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology, according to results of a late stage study released on Thursday. If approved, patisiran is forecast to reach annual sales of $1 billion...

  • Neos, a developer of attention deficit disorder treatments, rejected, as inadequate, a nearly $300 million all-cash bid from PDL that was more than a 40 percent premium to its market value. Neos will work with investment bank Jefferies LLC to explore its options and discuss a deal with other potential acquirers, the sources said. PDL BioPharma, based in Incline...

  • *FDA approval triggers $1.5 bln payment by AstraZeneca. LONDON, Oct 31- AstraZeneca has won U.S. approval for a new blood cancer drug several months earlier than expected, boosting its oncology portfolio- and requiring it to pay $1.5 billion to shareholders in the biotech company that first discovered the medicine. The British-based company had said it expected...